Lawrence Fong

MD

Genitourinary oncologist
Cancer immunotherapy program leader and lab researcher

About me

Dr. Lawrence Fong is a specialist in genitourinary cancer at UCSF Medical Center. He is particularly interested in tumor immunology – the role of the immune system in cancer – and developing immune-based treatments. He earned his undergraduate degree from Columbia University and his medical degree from Stanford University. He completed an oncology fellowship at Stanford, then joined the medical staff there in 1999. Fong came to UCSF in 2002.

  • Education

    Stanford University, 1992

  • Residencies

    University of Washington, Internal Medicine, 1994

  • Fellowships

    Stanford University, Oncology, 1997

  • Academic Title

    Professor

My goal is to improve treatment of cancer through immunotherapy.

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

My reviews

4.9

Overall Experience
75 Reviews
Being cared by Dr. Lawrence Fong is like a blessing from heaven.
Explained things in a way that was easy to understand
75 Reviews
Did the doctor pay attention to your concerns
75 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
75 Reviews
Knew the important information about your medical history
75 Reviews
The provider showed respect for what you had to say
75 Reviews
The provider spent enough time with me
75 Reviews
Decorative Caduceus

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

Decorative Caduceus

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...

Recruiting

Decorative Caduceus

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Da...

Radiographic progression free survival (rPFS) is defined as the time from the first day of study treatment with pembrolizumab to the date of documented radiographic tumor progression or death due to any cause, whichever occurs fir...

Recruiting

Decorative Caduceus

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

Recruiting

Decorative Caduceus

Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Pr...

A positive response is defined as a ≥40% increase in the number of infiltrating CD3+ T cells between the pre-treatment biopsy at baseline and the post-treatment RP specimen. Thus, a negative response is a <40% increase. The primar...

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab in Localized Bladder Cancer

The immunologic effect MPDL3280A activity within bladder tissue will be measured by a change in the CD3+ T cell count/µm2 between pretreatment biopsy and cystectomy tissue following MPDL3280A infusions. Tissue will be designated i...

Recruiting

Decorative Caduceus

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combinati...

Recruiting

Decorative Caduceus

Study of HPN424 in Patients With Advanced Prostate Cancer

In Part 1, measure incidence of dose limiting toxicities measured by adverse events and serious adverse events by dose level.

Recruiting

Decorative Caduceus

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants Wit...

Recruiting

Share